Literature DB >> 20873095

Head and neck oncology--2010, part II.

Eugene N Myers.   

Abstract

Part II this article reviewed the current state of the art in head and neck oncology. These include very important and stimulating new areas of interest including the marked acceptance of chemoradiation in favor of surgery in patients with cancer of the head and neck. The concept of HPV as a cause of cancer of the oropharynx is relatively new and very important in the epidemiology of these tumors. New modalities such as PET CT scanning and robotic surgery are discussed and appear to be very important in management of cancer of the head and neck. Endoscopic endonasal skull base surgery is another new high technology contribution to the field of head and neck surgery as is the use of endoscopic assisted thyroid surgery. These and other new concepts are discussed in this manuscript.

Entities:  

Mesh:

Year:  2010        PMID: 20873095     DOI: 10.1016/S0030-6657(10)70017-2

Source DB:  PubMed          Journal:  Otolaryngol Pol        ISSN: 0030-6657


  3 in total

1.  Evaluation of spheroid head and neck squamous cell carcinoma cell models in comparison to monolayer cultures.

Authors:  Lorenz Kadletz; Gregor Heiduschka; Julian Domayer; Rainer Schmid; Elisabeth Enzenhofer; Dietmar Thurnher
Journal:  Oncol Lett       Date:  2015-07-14       Impact factor: 2.967

2.  Analysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties.

Authors:  Paloma Bragado; Yeriel Estrada; Maria Soledad Sosa; Alvaro Avivar-Valderas; David Cannan; Eric Genden; Marita Teng; Aparna C Ranganathan; Huei-Chi Wen; Avnish Kapoor; Emily Bernstein; Julio A Aguirre-Ghiso
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

3.  The effect of 2D and 3D cell cultures on treatment response, EMT profile and stem cell features in head and neck cancer.

Authors:  Styliani Melissaridou; Emilia Wiechec; Mustafa Magan; Mayur Vilas Jain; Man Ki Chung; Lovisa Farnebo; Karin Roberg
Journal:  Cancer Cell Int       Date:  2019-01-14       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.